Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Decoding the therapeutic potential of extracellular vesicles in osteoarthritis: from biomolecular composition to clinical translation

Cheng W., Jin P., Liu W., Feng R., Zou L., Wang R.

Systematic Review on Osteoarthritis, published in Int J Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Int J Surg (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41382397
PMCID
PMC12695218
DOI
10.1097/js9.0000000000003219
Citations
1

Abstract (original English)

Osteoarthritis (OA) is a highly prevalent degenerative joint disorder that substantially compromises the quality of life in middle-aged and elderly individuals. Conventional therapeutic approaches exhibit limited efficacy, and there is an urgent need to identify more effective treatment options. Extracellular vesicles (EVs) serve as essential mediators of intercellular communication and have been established as crucial carriers for the delivery of bioactive molecules, encompassing DNA, RNA species (including mRNAs, lncRNAs, microRNAs), proteins, and lipids, in the pathogenesis and repair of OA. Comprehensive research has demonstrated that EVs derived from diverse sources possess significant therapeutic potential in mitigating OA progression. However, their dual role in simultaneously facilitating the transport of both beneficial and harmful factors necessitates a cautious interpretation. This review aims to systematically investigate the roles of EVs derived from various origins and subpopulations in mitigating OA progression, summarize recent advancements in EV delivery methodologies, and emphasize emerging strategies to enhance their therapeutic specificity and efficacy. By elucidating these mechanisms, this review seeks to address translational challenges and provide valuable insights into the development of next-generation EV-based therapeutics for OA treatment.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
AnimalsHumansOsteoarthritisUltracentrifugationExtracellular VesiclesTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research